Bringing the Oncology Community Together

Combination of Cixutumumab and Temsirolimus Demonstrates Improved Progression-Free and Encouraging Overall Survival for Bone and Soft Tissue Sarcoma

Gary Schwartz, MD
Published Online: Thursday, August 29, 2013
Memorial Sloan-Kettering Cancer CenterGary Schwartz, MD
Gary Schwartz, MD
Chief, Melanoma and Sarcoma Service Memorial Sloan-Kettering Cancer Center
New York, New York Dr. Yixuan Gong
The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody (cixutumumab) and an mTOR inhibitor (temsirolimus) in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas. The drug combination demonstrated clinical activity that merits the need for future trials.

The evidence of stable disease for more than 1 year in patients with solitary fibrous tumor and of partial response in patients diagnosed with Ewing sarcoma, osteosarcoma, or chondrosarcoma indicates that these drugs offer significant clinical benefit to subsets of patients. Toxicities were consistent with what has been reported previously for this drug combination.

Approximately 13,000 cases of soft-tissue and bone sarcoma are diagnosed annually in the United States. The median survival time from diagnosis for patients with metastatic disease is about 10 to 18 months.

Researchers at Memorial Sloan-Kettering Cancer Center undertook the multicenter, open-label, phase II study in 19 cancer centers nationwide. The findings were published in The Lancet Oncology in April 2013.

Progression-Free Survival at 12 Weeks

Nationwide, 388 patients aged ≥16 years who progressed after one (and up to four) prior chemo regimens, with a confirmed diagnosis of bone or soft-tissue sarcoma were allocated on the basis of IGF-1R expression by immunohistochemistry to one of three treatment groups: IGF-1R-positive soft-tissue sarcoma, IGF-1R-positive bone sarcomas, or IGF-1R-negative bone and soft-tissue sarcoma.

Of the 54 assigned to each group, the following were progression-free at 12 weeks by intentionto- treat analysis:
  • 17 in the IGF-1R-positive soft-tissue sarcoma group
  • 19 in the IGF-1R-positive bone sarcoma group
  • 21 in the IGF-1R-negative group
Although patients are still being treated, this trial has completed enrollment.

Median Progression-Free Survival

Median progression-free survival, overall survival, and response according to histological subtype and IGF-1R status were analyzed.

The median progression-free survival for the most common histological subtypes were 7.5 weeks for Ewing sarcoma, 6.0 weeks for osteosarcoma, 21.4 weeks for chondrosarcoma, 11.4 weeks for leiomyosarcoma, and 12.9 weeks for undifferentiated pleomorphic sarcoma.

For patients with osteosarcoma and leiomyosarcoma, IGF-1R status did not affect median progression- free survival. However, for Ewing sarcoma and chondrosarcoma, IGF-1R immunohistochemistry expression had a statistically significant effect on median progression-free survival.

For patients with Ewing sarcoma, the median progression- free survival was 5.7 weeks for those with IGF-1R-positive disease and 17.7 weeks for those with IGF-1R-negative disease. For patients with chondrosarcoma, the median progressionfree survival was 23.0 weeks for those with IGF-1R-positive disease and 8.1 weeks for those with IGF-1R-negative disease.

The primary endpoint of progression-free survival at 12 weeks ranged from 31% in patients with IGF-1R-positive, soft-tissue sarcomas to 39% in patients with IGF-1R-negative sarcoma.

Median Overall Survival

Median overall survival was 16.2 months for Ewing sarcoma, 14.6 months for leiomyosarcoma, not reached for osteosarcoma, 13.6 months for chondrosarcoma, 15.5 months for undifferentiated pleomorphic sarcoma, and 18.9 months for others. Patients with IGF-1R-negative Ewing sarcoma also had a numerical improvement in median overall survival when compared with those who were IGF-1R-positive.

Progression-Free Survival Overall Survival

Related Articles
Development of ALK Inhibitors in Advanced NSCLC
In this segment, panelists discuss crizotinib in ALK-positive non-small cell lung cancer, with a particular focus on determining where next-generation ALK inhibitors will fit into the treatment paradigm.
Brentuximab Vedotin-Induced Peripheral Neuropathy
In this segment, panelists discuss the side effects associated with brentuximab vedotin as a treatment for patients with lymphoid malignancies.
Brentuximab Vedotin in CD30-Positive Lymphoma
In this segment, panelists discuss the approval of brentuximab vedotin for patients with systemic anaplastic large-cell lymphoma and the continued investigation of the drug in other CD30-positive lymphoid malignancies.
Discovery Dilemma: Narrow “Superiority” Standard Is an Inferior Way to Evaluate Novel Therapies
The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.